Ariceum names Debiopharm director its chief business officer

Privately-held German biotech Ariceum Therapeutics, which is focused on developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has named Serge Sagodira as its chief business officer.

Dr Sagodira will oversee all business development aspects of the recently-launched company, leveraging his considerable expertise in licensing and transactions over a 20-year career in business development within the life sciences sector.

He joins Ariceum from family-owned Swiss pharmaceutical company, Debiopharm International, where he worked for almost 10 years across a number of licensing and transaction roles.